USANA Q3 2025 Preview: Short-Term Challenges Amid Strategic Transition
USANA Health Sciences faces short-term pain as Q3 preliminary results reveal declining profitability despite modest sales growth and ongoing business transition. USNA's new Brand Partner compensation plan and Hiya acquisition are causing temporary disruptions, but management expects double-digit Hiya growth and operational improvements by 2026. Valuation remains attractive, with USNA trading at significant discounts to sector averages, supported by a strong balance sheet and no debt.
USNA vs. STVN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
Is USANA Health Sciences (USNA) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy USANA Health Sciences (USNA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
USNA vs. STVN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks presents investors with the better value opportunity right now?
Are Investors Undervaluing USANA Health Sciences (USNA) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
USANA Health (USNA) Upgraded to Buy: Here's Why
USANA Health (USNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
USNA or ZTS: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences (USNA) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
USANA Health Sciences: Hiya's Potential Is Showing
USANA Health Sciences is resurfacing as an idea after a strong Q2 report. The direct selling business has continued to struggle with a decline in sales and active customers. A segment turnaround remains uncertain. The previous Hiya acquisition's potential is clearly showing. Operational expansion underlines massive long-term potential for USANA.
USANA Health Sciences, Inc. (USNA) Q2 2025 Earnings Call Transcript
USANA Health Sciences, Inc. (NYSE:USNA ) Q2 2025 Earnings Conference Call July 23, 2025 11:00 AM ET Company Participants Andrew Masuda - Director of Investor Relations Brent L. Neidig - Chief Commercial Officer G.
USANA Health Sciences (USNA) Q2 Earnings and Revenues Top Estimates
USANA Health Sciences (USNA) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.54 per share a year ago.
USANA Health Sciences: Premium Formulation, Discounted Valuation
USANA Health Sciences' pivot from MLM to omnichannel, highlighted by the Hiya Health acquisition, marks a strategic inflection point for renewed growth and relevance. The company's scientific credibility, strong balance sheet, and global reach position it well, despite recent revenue declines and heavy China exposure. Valuation is attractive at 12× forward earnings and 5× EBITDA, with catalysts including Hiya's growth, margin expansion, and potential buybacks.
